Objective. To investigate the efficacy of venlafaxine for neuropathic pain and review literature to determine if the medication provides adequate neuropathic pain relief.
Introduction
Neuropathic pain is the result of injury or dysfunction of the somatosensory system. Specifically, in neuropathic pain, damage to tissue affects the nervous system, which results in ectopic discharges that bypass transduction [1] . Depending on anatomical location, the source of the pain varies, such as neuropathic back pain being due to injury or disease that affects the nerve roots that innervate the spine and lower limbs [2] . This pain is characterized by the activation of abnormal pathways of pain at the peripheral nerves and posterior roots [3] . The pain manifestation can be focal, multifocal, or generalized. The neuropathy causes hypersensitivity in nerves due to unusual epinephrine-mediated transmission from one axon to another. This abnormal connection is known as ephaptic transmission [4] . The damaged nerves in the peripheral area cause basket formation, also known as sympathetic sprouting, which is located in the dorsal root ganglion (DRG). The combination of this sprouting with ephaptic transmission causes the release of epinephrine, which results in sympathetically maintained pain [5] .
The inflammatory reactions of the nerve mass can also contribute to the ectopic activity and play a crucial role behind spontaneous pain and allodynia. This allodynic skin can selectively impair function of nociceptors, causing temperature and pain sensation to be impaired and light stimuli, producing severe allodynia [6] . The inflammatory changes and damage to peripheral nerve fibers can express adrenergic receptors, which may also be contributing to the heightened sensitivity to sympathetic stimulation. Hyperexcited ectopic impulses are generated by expression of a variety of voltage-gated sodium channels, such as Nav1.3, Nav1.7, and Nav1.8 [7] . However, Nav1.3 is speculated to play the greatest critical role in neuropathic pain [8] . Research by Amir et al. showed that after nerve injury in the DRG, a sustained phasic discharge creates repeated firing. This sodium channel then alternates with voltage-independent potassium leak channels to oscillate membrane potentials [9] . The oscillations reach the threshold amplitude, causing ectopic impulses to be generated, therefore leading to sustained peripheral sensitization [10] . There is also the expression of voltage-gated calcium channels present in neuropathic pain, particularly channel subtype Cav 3.2 [11] . The calcium entry through theses voltagegated calcium channels stimulates the release of substance P and glutamate, resulting in modulation of pain at the dorsal horn [12] . At the cellular and tissue levels in neuropathic pain, there is redistribution of the Nav1.8 voltage-gated sodium channel subtype in nociceptors that express neuropathic physiology and microglial activation in the dorsal horn of the spinal cord. With neuropathic pain, presence of inflammatory mediators is present peripherally and centrally in the nervous system. The pain involves ongoing sensitization caused by either constant afferent stimulation from afferent nerves or from functional changes in the DRG present in sympathetic sprouting. There is also a significant decrease in substance P and CGRP and increases in galanin and neuropeptide Y, as per research analysis on afferent neurons and the spinal cord [13] .
Neuropathic pain can be divided into four broad categories: complex neuropathic disorders (such as complex regional pain syndrome), peripheral focal and multifocal nerve lesions (inflammatory, traumatic, or ischemic), peripheral generalized polyneuropathies (metabolic, hereditary, inflammatory, or toxic), and CNS lesions (e.g., spinal cord injury, stroke, multiple sclerosis) [14] . Clinical presentation of neuropathy involves at least one of the following three elements. The first is constant pain, which is present in the vast majority of cases, as it is spontaneous and usually described as a burning or tingling sensation, and less commonly as a cold sensation or aching. The second element is intermittent pain. Described by the patient as an electric shock, shooting, stabbing, or sharp sensation, which could be present for a few seconds to minutes and may occur several times a day. It is statistically more common in patients with pain secondary to peripheral nervous system or spinal cord injury. Finally, evoked pain, which is expressed as allodynia or hyperpathia, is more frequent after lesions in the brain due to damage to a part of the somatic nervous system [15] .
Literature shows that there is a high prevalence rate of chronic pain, particularly neuropathic pain, because unfortunately there is an absence of effective treatments. While for nociceptive pain opioids and nonsteroidal antiinflammatory drugs provide analgesia, the current medications appear to have a more minimal effect for treatment of neuropathic pain [1] .
One particular medication for neuropathic pain is venlafaxine. Venlafaxine immediate release was the first serotonin norepinephrine re-uptake inhibitor (SNRI) to be marketed in the United States and was approved by the US Food and Drug Administration (FDA) in 1993. In 1997, the extended release (XR) version of the medication was approved by the FDA and is dosed once per day (as opposed to the twice-a-day dosing of immediate release). Venlafaxine is approved by the FDA for the following conditions: major depression, generalized anxiety disorder, panic disorder, and social phobia [16] .
It should be stated that literature and research give evidence that a balanced inhibition of the uptake of both serotonin and noradrenaline is considered to be important also for its analgesic effect. Research also indicates that selective serotonin re-uptake inhibitors (SSRIs) are fairly ineffective in analgesia treatment. These SSRIs were studied because tricyclic antidepressants (TCAs), which inhibit both serotonin and norepinephrine, have proven to be very effective in pain relief. Since SSRIs are not effective and TCAs are, it is now widely thought that it is specifically the inhibition in reuptake of norepinephrine and not serotonin that plays a crucial role in analgesia. Therefore, while not FDA approved for neuropathic pain treatment, venlafaxine has shown to have promising findings as an analgesic agent, and this will be the focal point of investigation in this review [17] .
The only drugs to treat neuropathic pain presently approved by the FDA include carbamazepine for trigeminal and glossopharyngeal neuralgias, gabapentin for postherpetic neuralgia, duloxetine for the treatment of painful diabetic neuropathy, topical lidocaine for postherpetic neuralgia, and pregabalin for control of postherpetic neuralgia and painful diabetic peripheral neuropathy [18] .
Venlafaxine is a phenylethylamine derivative as well as a chimeric compound, in which both R-and S-enantiomers block the presynaptic reuptake of serotonin (5-hydroxtryptamine, 5-HT) and norepinephrine. The major metabolite created by cytochrome p450-2DE, R-O-desmethylvenlafaxine (ODV), has been reported as the most potent inhibitor of both norepinephrine and serotonin re-uptake [19] . Research indicates that venlafaxine inhibits serotonin re-uptake at lower doses (less than 100 mg/day), whereas norepinephrine re-uptake increases over the dose range of 100 to 375 mg/day [20] . Additionally, venlafaxine has a 30-fold higher affinity for the re-uptake inhibition of serotonin compared with norepinephrine [20] .
The elimination half-life (t 1/2 ) for the parent compound is five hours, and 11 hours for ODV. Prolonged half-life due to decreased clearance appears with hepatorenal impairments, additionally with hemodialysis. Time to peak concentration (T max ) for the immediate release dosage form is two hours, and three hours for ODV. The XR dosage form provides T max 5.5 hours, and for ODV is nine hours. Clinical consideration should be involved when initiating doses of XR dosage form to the patient's most painful daily pain period to capitalize on the T max occurrence.
Inhibition of both serotonin and noradrenaline re-uptake is the pharmacologic explanation for the medications' antidepressant activity [21] . Based on the literature, it is suggestive that venlafaxine is effective for the management of neuropathic pain at doses of 150 mg per day or higher [22] . Consequently, venlafaxine in a clinical setting has proven to be be a common choice for pharmacotherapy for physicians when treating neuropathic pain.
While proving to be an efficacious medication for neuropathic pain, venlafaxine's adverse effect profile should be noted. Cardiac conduction abnormalities and hyponatremia have been reported in a small number of patients. Hypertension is also a frequent side effect of venlafaxine, and therefore blood pressure should be closely monitored in patients prescribed this medication. In addition, venlafaxine should have a prolonged slow taper over weeks when treatment is being discontinued because a discontinuation withdrawal syndrome has been described [23] .
As a result, we systematically reviewed literature to investigate the efficacy of venlafaxine for the treatment of neuropathic pain. The aim for this review is to provide evidence and well-established, researched data on the efficacy of venlafaxine for the treatment of neuropathic pain and how beneficial it is for clinicians to prescribe the agent.
Methods
Literature was reviewed on MEDLINE using a variety of key words. These key words include: "venlafaxine and pain," "venlafaxine ER and pain," "venlafaxine XR and pain," "venlafaxine and neuropathic pain," "venlafaxine and neuropathy," "SSRI and neuropathic pain," "SSRI and neuropathy," "SNRI and neuropathic pain," "SNRI and neuropathy," "serotonin reuptake inhibitor and neuropathic pain," "serotonin reuptake inhibitor and neuropathy," "serotonin norepinephrine reuptake inhibitor and neuropathic pain," "serotonin norepinephrine reuptake inhibitor and neuropathy." Literature was reviewed on MEDLINE that dates from 1968 until July 2016. With the results, the papers were reviewed using the Preferred Reporting in Systematic and MetaAnalyses (PRISMA) guidelines. The inclusion criteria include: patients older than age 18 years, neuropathic pain being the primary indicator for venlafaxine treatment, monotherapy only of venlafaxine, studies written in English, and all clinical trials (randomized control trials, blinded or unblinded, prospective, retrospective and cross-sectional) that reported an analgesia outcome with regards to a scale, thus objectively analyzing the clinical response elicited by venlafaxine. Exclusion criteria include: omitting reviews, case reports, case series, nonhuman (animal model) studies, non-English studies, venlafaxine as an adjunct therapy, venlafaxine used for non-neuropathic pain treatment and venlafaxine used primarily for a medical disorder (unrelated to pain).
Two authors (RA, AB) reviewed all trials for screening selection and extraction. Seven hundred seventy-eight articles were screened. The first screening involved reviews, excluding irrelevant records. This resulted in 29 articles. The second screening involved the two reviewers analyzing the remaining studies to ensure they met the inclusion criteria, and the full texts of the articles were obtained to formally be discussed and be included in the final manuscript. This resulted in a final number of 13 articles.
As mentioned, clinical trials, prospective, retrospective, and cross-sectional were all included in this PRISMA systematic review. The purpose of this review is to present a detailed and comprehensive review of all the literature involved with venlafaxine and treatment of neuropathic pain. The Harden model was utilized to break down the studies into different levels of review [24] . Table 1 below outlines the levels.
Results
Of the 13 articles, 11 represented level II evidence of venlafaxine for neuropathic pain, two articles for level III evidence. The screening process can be viewed on the PRISMA flow chart ( Figure 1) . The results of the data are summarized in Tables 2 and 3 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
A total of 13 studies were reviewed, which are organized chronologically. Eleven of the studies were randomized control studies, one was prospective, and one was retrospective case-control. Of the 13 studies reviewed, 11 studied had a placebo comparator group. Of these 11 studies, nine that compared venlafaxine with placebo showed marked, statistically significant improvement in neuropathic pain reduction, with the remaining two studies showing no statistically significant difference. There are also four studies that investigated venlafaxine against another medication, with head-to-head trials. Three of these studies showed no statistically significant difference between venlafaxine, imipramine, gabapentin, and pregabalin (Sindrup et al., Amr et al., and Razazian et al., respectively). One of the studies, Jia et al., compared it with carbamazepine and provided evidence that venlafaxine is in fact superior to treating neuropathic pain [30] . The results showed that venlafaxine compared with carbamazepine had statistically significant pain intensity reduction at days 5, 7, 10, and 14 (P ¼ 0.02, P ¼ 0.03, P ¼ 0.003, and P ¼ 0.001, respectively) [30] .
A variety of scales for measure of pain were used throughout the literature review. For instance, Durand et al. showed that full relief was more frequent in the venlafaxine arm (31.3% vs 5.3%), as well as venlafaxine being significant for treatment of pins and needles sensation when using the numeric rating scale [33] . Even on retrospective studies, the use of numeric rating scale in Kus et al. illustrated the clinical significance of venlafaxine, with symptomatic relief at 53.5%, 58.3%, and 45.2% in the treatment arm vs 0% in the control arm in each of the first, second, and third. [37] . With the McGill Pain Questionnaire, Kadiroglu et al. showed in their study the reduction rate in the severity of pain was 53% in the venlafaxine treatment group vs 22% in the control group [31] . Treating Neuropathic Pain with Venlafaxine Table 3 Level III-studies of venlafaxine for treatment of neuropathic pain reduction with treatment [35] . Consequently, it is clear that there is significant clinical response to venlafaxine through a variety of pain scales used. However, even on studies that used nonobjective methods, nonscale measuring of analgesic relief such as in the Tasmuth et al. study, showed that the average pain relief (diary) and the maximum pain intensity (retrospective assessment by the computer program) were significantly lower with venlafaxine compared with placebo [25] . It should also be noted that one study showed even more significant pain relief when using higher doses of venlafaxine (at least 150 mg) [29] . Rowbotham et al. also provided statistical evidence that higher-dose (150-225 mg/day) venlafaxine was also significantly more effective than 75 mg/day after six weeks of treatment (P ¼ 0.0006) [29] .
Discussion
Neuropathy has proven to be very difficult to manage for clinicians, and there are numerous medications for physicians to choose from. While there are other available options, venlafaxine is sometimes overlooked and, based on the results of this literature review, should be more widely used for the treatment of neuropathic pain.
It is evident from the data that venlafaxine is in fact an effective medication for the treatment of neuropathic pain, whether it is acute or chronic. Richards et al. discuss why they believe venlafaxine is not as effective for spinal cord injury (SCI) compared with other types of neuropathic pain [35] . They stated that in people with SCI there is an association with abnormal spontaneous neuronal activity in dorsal horn neurons above and below the injury level, which has been shown in literature to be responsive to calcium channel agents like gabapentin [35] . Therefore, the differing underlying pain pathophysiology is a likely reason for the ineffectiveness of venlafaxine. However, it is evident that the majority of the literature on venlafaxine and neuropathic pain is focused on peripheral pain syndromes such as postherpetic neuralgia and diabetic neuropathy [35] . In the other study that did not show any pain reduction with venlafaxine, Forsell et al.suggested a few possible explanations for the lack of efficacy in atypical facial pain (AFP). One suggestion was the dose was not high enough (only 75 mg/day) and perhaps needed higher dosing (150-225 mg/day). The authors also suggested that the heterogeneity of AFP diagnosis may have confounded the findings as there is no unified, defined diagnostic criterion for AFP [27] .
However, it should also be noted that against other medications, venlafaxine did not perform better, apart from Jia et al., where it had a more robust response compared with carbamazepine. Razazian et al.showed that venlafaxine was inferior to gabapentin (46.6 and 34.4, respectively) in neuropathic pain reduction, as well as that a statistically significant proportion of patients treated with pregabalin were better responders compared with venlafaxine (P ¼ 0.004) [34] . Not only was venlafaxine inferior to pregabalin with regards to efficacy, but venlafaxine had significantly higher adverse effects compared with both carbamazepine and pregabalin as the number of patients withdrawn was significantly higher (P ¼ 0.01) [34] .
Sindrup et al.studied venlafaxine compared with imipramine, which showed no statistical difference in efficacy. While the NNT for imipramine is 2.7 (compared with 5.2 for venlafaxine), the authors noted that the confidence interval for imipramine was quite wide [26] . Amr et al.also investigated venlafaxine head to head with gabapentin. As mentioned in the two aforementioned studies, there was no difference between venlafaxine and the comparator gabapentin in efficacy apart from pain relief after movement (P < 0.0001). In addition, there was no difference in side effects between venlafaxine and gabapentin as both groups complained of nausea, vomiting, dizziness, and drowsiness [32] .
Despite this, overall the studies that compared venlafaxine with placebo in this manuscript demonstrate the neuropathic analgesic properties of venlafaxine and strongly suggest that clinicians involved with pain management of neuropathy should consider this agent. The promising results from this review illustrate the implications that venlafaxine has to offer physicians that treat neuropathic pain on a daily basis. Nevertheless, the studies that compared venlafaxine with other agents show that there is not any advantage to using this medication.
A similar Cochrane systematic review by Gallagher et al. evaluated only six randomized double-blind trials [20] . The reasoning behind our review studying five more trials is due to the fact that two of the randomized control trials were published after Gallagher et al. ' [31] . The severity of pain was greatly improved by two weeks, and this trend continued at the fourth and eight weeks of the study. At the conclusion of the study, the reduction rate in the severity of the pain was 53% compared with 22% in the control group (P < 0.05) [31] . Consequently, we feel these results are of value and warranted to be included in our systematic review.
Two other studies (Amr et al. and Durand et al) were randomized controlled trials that reported results after 10 days of venlafaxine therapy. Gallagher et al.required the studies to report results after at least 14 days of venlafaxine treatment to be considered in their systematic review. We decided to provide the results of these studies as we felt clinicians would benefit from these particular trials. Amr et al.studied 150 subjects on venlafaxine and after 10 days showed significant reduction in burning pain compared with control (P ¼ 0.0018), as well as stabbing pain compared with control and gabapentin (P ¼ 0.003 and P ¼ 0.028, respectively) [32] . Durand et al.also showed full pain relief from venlafaxine when compared with placebo, 31.3% vs 5.3% (P ¼ 0.03), as well significant (P < 0.001) improvement in the pins and needles sensation in patients post-chemotherapy-induced neuropathy [33] . While these two studies investigated short-term response within only 10 days of treatment, this data is still very informative to clinicians who are interested in management of patients with acute neuropathic pain, such as immediate postoperative settings.
However, it should be noted that there are side effects associated with venlafaxine that clinicians should be aware of. There are certain studies that have specifically monitored side effects. Forssell et al. stated that the incidence of adverse effects was similar in the venlafaxine and placebo periods but participants reported more severe dry mouth and sweating while taking venlafaxine compared with placebo [27] . Rowbotham et al. reported from their study that nausea, dyspepsia, sweating, and somnolence were the most common adverse effects in patients taking venlafaxine. The same authors give evidence that 10% of placebo, 9% of venlafaxine 75 mg, and 12% of venlafaxine 150 to 225 mg groups had a serious adverse effect [28] . Finally, Jia et al.reviewed side effects that affected 10% of participants, which included mild gastrointestinal discomfort, dizziness, and somnolence [30] .
Literature indicates that the adverse effect profile of venlafaxine at a dose of 75 mg/day is very similar to that of a selective serotonin re-uptake inhibitor agent (gastrointestinal disturbances, sexual dysfunction). However, at higher doses, patients are more likely to experience side effects secondary to norepinephrine uptake (increased sweating, tachycardia, hypertension, and dry mouth) [38] . Hypertension with use of venlafaxine is dose dependent, with prevalence at 0% at 75 mg daily, which to 13% when a patient is prescribed greater than 300 mg/day [39] .
In addition to adverse effects, there are drug interactions that need to be considered. Venlafaxine is primarily metabolized through the liver (2D6, 3A3/4 isoenzymes) and is therefore at risk to cause drug interactions, as well as to be metabolically susceptible to genetic polymorphism (2D6) [40] . Common interactions include: increased toxic effects of CNS depressants, SSRIs, CYPD2D6 inhibitors, and CYP3A4 inhibitors; effects can be decreased by CYP3A4 inducers and, due to the risk of hypertensive crisis, it is absolutely contraindicated with monoamine oxidase inhibitors (MAOIs). Hepatic inhibitors yield increased adverse effects, and hepatic induction diminishes efficacy [41] .
The studies reviewed have several limitations. First, the sample sizes for a few of the studies are relatively small. Second, there is variability in the selection of patients; despite all of them having neuropathic pain, it is evident that there are variations of neuropathic pain that thus could potentially impact the results. There is also variability in the research methodology used, as well as the methods of assessment (different pain rating scales utilized). Third, there are inconsistencies between the studies with regards to doses used, which again could alter the results as it is difficult to report findings with variation of medication doses. Fourth, there is variation in the time venlafaxine was administered, as well as the follow-up period varying from study to study, again being another inconsistency when reporting the studies. Lastly, it should be noted that the literature in this particular area is quite limited, with only 13 studies available for analysis and little empirical data.
In conclusion, venlafaxine is a safe and well-tolerated analgesic drug for the symptomatic treatment of neuropathic pain, and while the present evidence is suggestive of its efficacy, further research is needed to continue to expand on these findings. While it may not be beneficial over other alternative medications, there is data to show it should be strongly considered as an agent for the treatment of neuropathic pain.
